Researchers in this study are trying to find out if treating platinum resistant ovarian cancer with an immunotherapy drug called embrolizumab and the chemotherapy drug paclitaxel is better than just treating with paclitaxel on it’s own. Platinum resistance means that your cancer no longer responds to platinum based chemotherapy (e.g carboplatin). …

In this study, researchers want to find out how safe and effective it is to use two new drugs, alone or in combination, to treat recurrent, low grade serous ovarian cancer (LGSOC).The drugs used in this trial are both a type of drug called a kinase inhibitor. Kinase inhibitors block cancer cell growth.The drugs involved in this trial are:Defactinib…

The purpose of this study is to determine if a combination of two different anti-cancer drugs are safe and effective in treating different types of solid tumours, including ovarian cancer. It's for women with ovarian cancer whose cancer has continued to spread and grow despite standard chemotherapy treatments. The drugs involved in this trial are k…

In this study, researchers want to test a new blood test that they have developed which can tell doctors if a person is responding to the drug bevacizumab. Bevacizumab is a type of targeted therapy that works by blocking a growth factor (like a hormone) that makes blood vessels. This growth factor is called VEGF. By blocking VEGF, some cancers i…

Researchers in this study are trying to find out more about the mechanisms of action of a drug called olaparib. olaparib is a PARP inhibitor which is a targeted treatment for ovarian cancer. Researchers wish to find out why some women's ovarian cancer responds well to olaparib while other ovarian cancers don't. This information will help them to be…

The purpose of this trial is to find out how safe and effective it is to have either one or two immunotherapy drugs alongside the parp inhibitor Rucaparib. Researchers want to find out if using the different combination of drugs will prolong the time it takes for your cancer to come back compared with being treated with Rucaparib on its own. The…

Recruitment to this trial is currently paused. The researchers in this trial are looking to find how out how well the drug ceralasertib (on its own) and the combination of the drugs ceralasertib and olaparib work in rarer types of gynaecological cancers. The drugs used in this clinical trial are: Ceralasertib is a drug called an ATR inh…

Around half of women diagnosed with ovarian cancer are over the age of 65. Older women may have different medical and social problems than those seen in younger women. This may result in them being offered less intensive chemotherapy options to treat their ovarian cancer. Research has already shown that in older people who don’t have cancer, und…

This audit is looking to find out if there are any differences in how many complications women develop after gynaecological cancer surgery in countries that have different incomes. It's hoped that the information collected will benefit women needing surgery both now and in the future. This information will help surgeons and researchers to: …

This trial is looking to find better treatments for women with ovarian cancer that has come back. The trial is looking to find out if the drugs olaparib and cediranib are safe and work better than the standard chemotherapy drug paclitaxel. The drugs involved in this trial are: Paclitaxel – the known drug. This is a chemotherapy drug given …

Olaparib is a type of targeted treatment known as a PARP inhibitor. It blocks an enzyme called PARP, which helps damaged cancer cells to repair themselves. When PARP doesn't work the cancer cells won't be able to repair themselves and will die. Because of this, drugs such as olaparib are known to lengthen the amount of time between receiving chemot…

In cases where ovarian, fallopian tube or peritoneal cancer has come back (recurrence or relapse) and it has become resistant to platinum-based chemotherapy, new treatment strategies and new drugs are needed to better treat this disease. This study tests a new drug both in combination with a known treatment and alone, to find out if the differe…